Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Emergent Biosolutions
(NY:
EBS
)
8.750
-0.530 (-5.71%)
Streaming Delayed Price
Updated: 1:29 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Emergent Biosolutions
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm
April 29, 2021
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
EMERGENT SHAREHOLDERS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
April 29, 2021
From
Lieff Cabraser Heimann & Bernstein, LLP
Via
Business Wire
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 28, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
April 28, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
A Preview Of Emergent BioSolutions's Earnings
April 28, 2021
Emergent BioSolutions (NYSE:EBS) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings...
Via
Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS
April 27, 2021
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 27, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.’s Directors and Officers for Breach of Fiduciary Duties – EBS
April 27, 2021
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
April 27, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Is There Any Hope Left for Emergent BioSolutions?
April 27, 2021
The go-to government contractor is in deep trouble. Should investors buy the dip?
Via
The Motley Fool
Exposures
COVID-19
EBS INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.
April 26, 2021
NEW YORK, NY / ACCESSWIRE / April 26, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors...
From
Bernstein Liebhard LLP
Via
AccessWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
April 26, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
SHAREHOLDER ALERT: Robbins LLP Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders
April 23, 2021
From
Robbins LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
April 23, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ
April 23, 2021
The U.S. is expected to announce its decision on Johnson & Johnson’s (NYSE: JNJ) single-shot COVID-19 vaccine on whether it should be back in circulation...
Via
Benzinga
Exposures
COVID-19
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 23, 2021
From
The Schall Law Firm
Via
Business Wire
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)
April 22, 2021
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
April 22, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 22, 2021
From
The Schall Law Firm
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 22, 2021
Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
April 22, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
April 22, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
Why Emergent BioSolutions Stock Is Falling Again Today
April 22, 2021
An analyst lowered his price target on the stock.
Via
The Motley Fool
Exposures
COVID-19
Stocks That Hit 52-Week Lows On Thursday
April 22, 2021
On Thursday morning, 5 companies achieved new lows for the year. Interesting Points: Emergent BioSolutions (NYSE:EBS) was the largest, in terms of market cap, to...
Via
Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
April 21, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
April 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,...
Via
Benzinga
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS
April 21, 2021
From
The Rosen Law Firm, P.A.
Via
Business Wire
FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training
April 21, 2021
The FDA concluded its inspection of Emergent BioSolutions Inc’s (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.